Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More
Posters

Sparsentan Publications 2023

Learn More
Publications IgAN

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

View
Medical Information IgAN

SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy

Learn more
Medical Information IgAN

SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design

Learn more
Medical Information FSGS IgAN Other

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results

Learn more
Medical Information FSGS

Phase 2 DUET Study Published in the Journal of the American Society of Nephrology

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Safety Data Sheet

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study

Learn more
Medical Information FSGS IgAN

FILSPARI (sparsentan) – Hyperkalemia

Learn more